The role of SET/I2PP2A in canine mammary tumors

[1]  J. Xing,et al.  Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway. , 2015, Molecular medicine reports.

[2]  M. Vitek,et al.  The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma , 2015, The Journal of veterinary medical science.

[3]  M. Cristofanilli,et al.  Molecular characterization and targeted therapeutic approaches in breast cancer , 2015, Breast Cancer Research.

[4]  J. Sur,et al.  Effects of Obesity and Obesity-Related Molecules on Canine Mammary Gland Tumors , 2015, Veterinary pathology.

[5]  Hongsheng Wang,et al.  Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer , 2015, Oncotarget.

[6]  George A. Calin,et al.  From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies , 2015, Front. Oncol..

[7]  F. Rojo,et al.  PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects , 2015, Oncotarget.

[8]  Hao Liu,et al.  SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell. , 2014, Cellular signalling.

[9]  F. Rojo,et al.  Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer , 2014, Clinical Cancer Research.

[10]  L. Cai,et al.  NF-κB Affects Proliferation and Invasiveness of Breast Cancer Cells by Regulating CD44 Expression , 2014, PloS one.

[11]  H. Zhang,et al.  Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells , 2014, Breast Cancer Research.

[12]  Colin J. Daniel,et al.  Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer , 2014, Proceedings of the National Academy of Sciences.

[13]  T. Mizuno,et al.  Characterization of SET/I2PP2A Isoforms in Dogs , 2014, The Journal of veterinary medical science.

[14]  M. Caligiuri,et al.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. , 2013, The Journal of clinical investigation.

[15]  T. Uchide,et al.  L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour. , 2013, Veterinary journal.

[16]  G. Stark,et al.  PHF20 regulates NF-κB signalling by disrupting recruitment of PP2A to p65 , 2013, Nature Communications.

[17]  D. Perrotti,et al.  Protein phosphatase 2A: a target for anticancer therapy. , 2013, The Lancet. Oncology.

[18]  L. Pannell,et al.  DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin , 2012, Oncogene.

[19]  Kuen-Feng Chen,et al.  CIP2A is a target of bortezomib in human triple negative breast cancer cells , 2012, Breast Cancer Research.

[20]  F. Gärtner,et al.  Canine tumors: a spontaneous animal model of human carcinogenesis. , 2012, Translational research : the journal of laboratory and clinical medicine.

[21]  C. Van Ginneken,et al.  Canine mammary tumours, an overview. , 2011, Reproduction in domestic animals = Zuchthygiene.

[22]  M. Vitek,et al.  SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. , 2011, Blood.

[23]  V. Zappulli,et al.  Development, Anatomy, Histology, Lymphatic Drainage, Clinical Features, and Cell Differentiation Markers of Canine Mammary Gland Neoplasms , 2011, Veterinary pathology.

[24]  A. Teleman,et al.  PP2A regulatory subunit PP2A-B' counteracts S6K phosphorylation. , 2010, Cell metabolism.

[25]  D. Brautigan,et al.  Endotoxin Conditioning Induces VCP/p97-mediated and Inducible Nitric-oxide Synthase-dependent Tyr284 Nitration in Protein Phosphatase 2A* , 2010, The Journal of Biological Chemistry.

[26]  E. Colado,et al.  The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair , 2009, Leukemia.

[27]  M. Mochizuki,et al.  Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their E-cadherin expression. , 2006, Veterinary and comparative oncology.

[28]  F. Queiroga,et al.  Role of steroid hormones and prolactin in canine mammary cancer , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  V. Janssens,et al.  Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. , 2001, The Biochemical journal.

[30]  P. McNamara,et al.  Regulation of Histone Acetylation and Transcription by INHAT, a Human Cellular Complex Containing the Set Oncoprotein , 2001, Cell.

[31]  N. Shikama,et al.  Functional Interaction between Nucleosome Assembly Proteins and p300/CREB-Binding Protein Family Coactivators , 2000, Molecular and Cellular Biology.

[32]  K. Nagata,et al.  Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor. , 1999, Biochemical and biophysical research communications.

[33]  S. Schreiber,et al.  Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Chen,et al.  Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. , 1992, Science.

[35]  Marieke,et al.  Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene , 1992, Molecular and cellular biology.

[36]  M. Vitek,et al.  A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma. , 2013, The Journal of veterinary medical science.